Current Concepts in the Management of Relapsed/Refractory Multiple Myeloma: Considerations With Bispecific Anti-BCMA Antibodies
Podcast 3: Managing Relapsed/Refractory Multiple Myeloma: Considerations for Newer Therapies
Post-Test/Evaluation

Questions marked with a * are required

20%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

In a patient who has developed resistance to at least four courses of multiple myeloma therapy, an FDA-approved agent or clinical trial of an investigational agent from which of the following classes would be most appropriate?

A. Combination therapy incorporating anti-CD38 antibodies

B. Proteasome inhibitors

C. Alkylating agents

D. B cell maturation antigen (BCMA) therapies

Brett is a 67-year-old man with multiple myeloma. He has previously received a proteasome inhibitor, an immunomodulatory agent, a CD38-targeting monoclonal antibody, and an alkylating agent, but he currently presents with another relapse. Which of the following approaches would you take for this patient at this time?

A. Try another course of PI or IMiD

B. Strongly consider CAR-T, a bispecific antibody, salvage transplant and/or a novel agent

C. Recommend only an FDA-approved agent; do not consider enrolling the patient in a clinical trial at this time

D. Do not consider autologous peripheral blood stem cell transplant if the patient has never been transplanted with them